HHS (through SAMHSA) announced a State Opioid Response (SOR) grant funding of nearly $1.5 billion to help address the nation’s opioid addiction and overdose epidemic.
HHS has launched the PandemicX 2022 cohort, a program to accelerate private-public collaboration of 15 health tech startups.
NIH has awarded approximately $577 million to establish nine Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern.
The U.S. Department of Health and Human Services and U.S. Education Department have launched a joint-department effort to expand school-based health services.
FDA has granted breakthrough device designation to Roche’s Elecsys Amyloid Plasma Panel, a new solution to enable Alzheimer’s disease to be detected earlier.
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
The Department of Health and Human Services (HHS) through the Substance Abuse and Mental Health Services Administration (SAMHSA) announced two Certified Community Behavioral Health Clinics (CCBHCs) funding opportunities to expand and increase access to evidence-based mental health and substance use services for Americans.
The Department of Health and Human Services (HHS) announced more than $413 million in Provider Relief Fund (PRF) payments to more than 3,600 providers across the country.
New federal protections shield millions of consumers from surprise medical bills, which are unexpected bills from out-of-network providers, out-of-network facilities or out-of-network air ambulance providers.
An investigational antisense oligo-nucleotide (donidalorsen) that acts by degrading plasma prekallikrein messenger RNA was evaluated in patients with hereditary angioedema (HAE) and C1 inhibitor deficiency to assess whether this agent can reduce the frequency of angioedema attacks and the burden of disease.
A new systematic review and meta-analysis conducted by U.S. and Nepalese collaborators supports the use of IVIG with glucocorticoids compared to IVIG alone.
Researchers at the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine are developing a COVID-19 vaccine using a conventional method that will make the production and distribution cheaper and more accessible.
